Table 4.
Features of ESUS patients ≤ 50 years vs. >50 years.
|
ESUS patients |
|||||
|---|---|---|---|---|---|
|
Age ≤50 yrs(N=78) |
Age >50 yrs(N=273) |
||||
| Na | % or Mean | Na | % or Mean | P valueb | |
| Mean age (yrs) | 78 | 40 (9) | 273 | 68 (10) | <0.0001 |
| Men (%) | 78 | 67 | 272 | 54 | 0.0688 |
| Diabetes (%) | 78 | 21 | 273 | 26 | 0.3755 |
| Hypertension (%) | 78 | 36 | 270 | 73 | <0.0001 |
| Current tobacco use (%) | 78 | 28 | 273 | 21 | 0.1707 |
| Coronary artery disease (%) | 74 | 7 | 258 | 11 | 0.3812 |
| History of stroke or TIA prior to index stroke (%) | 78 | 5 | 270 | 21 | 0.0006 |
| Heart failure (%) | 73 | 0 | 258 | 2 | 0.3452 |
| Hyperlipidemia (%) | 72 | 28 | 254 | 43 | 0.0285 |
| Peripheral vascular disease (%) | 71 | 0 | 236 | 4 | 0.1240 |
| Antiplatelet therapy at the time of index stroke (%) | 76 | 11 | 270 | 36 | <0.0001 |
| Anticoagulant therapy at the time of index stroke (%) | 72 | 3 | 255 | 1 | 0.2117 |
| Median NIHSS score near admission (IQR) | 58 | 3 (1, 7) | 228 | 4 (2, 9) | 0.0553 |
| IV TPA for index stroke (%) | 78 | 9 | 269 | 19 | 0.0551 |
| Death within 30 days (%) | 67 | 1 | 208 | 2 | >0.90 |
| Antithrombotic therapy at discharge | |||||
| ASA (%) | 78 | 59 | 263 | 53 | 0.3669 |
| Clopidogrel (%) | 78 | 18 | 263 | 19 | >0.90 |
| Dual antiplatelet (%) | 78 | 13 | 263 | 20 | 0.1835 |
| Warfarin/vitamin K antagonist only (%) | 78 | 8 | 263 | 3 | 0.0980 |
| Rivaroxaban, dabigatran or apixaban only (%) | 78 | 1 | 263 | 2 | >0.90 |
| None only (%) | 78 | 0 | 263 | 2 | 0.5776 |
ASA: aspirin; ESUS: embolic strokes of undetermined source; IQR: interquartile range; TIA: Transient Ischeamic Attack; IV: Intra venous; TPA: Tissue plasminogen activator; yrs: years.
aOnly complete cases used to calculate the percentages.
bP values for categorical comparison – Fisher's exact test; P values for continuous comparison – Wilcoxon rank-sum test.